Rather than follow in the footsteps of other foundation-backed mid-size European pharmas that have largely concentrated on a single therapeutic area and looked to new markets for growth, Servier has determined its path to sustainability leads through new disease areas.

The French pharma has grown its cardiovascular business into the fifth biggest among European pharma companies and now wants to do the same in cancer while bolstering its diabetes, rheumatology and neurology pipelines.